Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11676
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTebbutt, Niall Cen
dc.contributor.authorParry, M Men
dc.contributor.authorZannino, Den
dc.contributor.authorStrickland, A Hen
dc.contributor.authorVan Hazel, G Aen
dc.contributor.authorPavlakis, Nen
dc.contributor.authorGanju, Ven
dc.contributor.authorMellor, Den
dc.contributor.authorDobrovic, Alexanderen
dc.contributor.authorGebski, V Jen
dc.date.accessioned2015-05-16T01:17:38Z
dc.date.available2015-05-16T01:17:38Z
dc.date.issued2013-02-14en
dc.identifier.citationBritish Journal of Cancer 2013; 108(4): 771-4en
dc.identifier.govdoc23412099en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11676en
dc.description.abstractCetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel and cetuximab as a second-line treatment in docetaxel-refractory oesophagogastric cancer.Patients received docetaxel 30 mg m(-2) on days 1 and 8, every 3 weeks and cetuximab 400 mg m(-2) on day 1, then 250 mg m(-2) weekly. Biomarker mutation analysis was performed.A total of 38 patients were enrolled. Response rates were PR 6% (95% CI 2-19%), s.d. 43% (95% CI 28-59%). Main grade 3/4 toxicities were febrile neutropenia, anorexia, nausea, diarrhoea, stomatitis, and acneiform rash. Median progression-free and overall survival were 2.1 and 5.4 months, respectively. A landmark analysis showed a trend to improved survival times with increased grade of acneiform rash. No KRAS, BRAF or PIK3CA mutations were observed.Cetuximab and docetaxel achieve modest responses rates, but maintain comparable survival times to other salvage regimens with low rates of toxicity.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAntibodies, Monoclonal.administration & dosageen
dc.subject.otherAntibodies, Monoclonal, Humanizeden
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.adverse effects.therapeutic useen
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherDrug Resistance, Neoplasmen
dc.subject.otherEsophageal Neoplasms.drug therapy.mortalityen
dc.subject.otherEsophagogastric Junctionen
dc.subject.otherHumansen
dc.subject.otherMiddle Ageden
dc.subject.otherQuality of Lifeen
dc.subject.otherStomach Neoplasms.drug therapy.mortalityen
dc.subject.otherTaxoids.administration & dosageen
dc.titleDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish Journal of Canceren
dc.identifier.affiliationniall.tebbutt@ludwig.edu.auen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australiaen
dc.identifier.doi10.1038/bjc.2013.41en
dc.description.pages771-4en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/23412099en
dc.contributor.corpauthorAustralasian Gastro-Intestinal Trials Group (AGITG)en
dc.type.austinJournal Articleen
local.name.researcherDobrovic, Alexander
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.